Ozempic follows a fixed step-up schedule, not a single dose. The label starts everyone at 0.25 mg once a week for four weeks, moves to 0.5 mg for four weeks, and only then climbs toward 1 mg or 2 mg. The starting dose is not a treatment dose. It exists to let the stomach adjust before the amount rises. Reaching a full maintenance dose takes at least two months and often longer, and that slow climb is the whole design, not a delay.
Why does the schedule start so low?
The 0.25 mg starting dose is chosen for tolerance, not effect. Semaglutide slows how fast the stomach empties, and the most common early complaints are nausea, reflux, and constipation. Beginning low and rising gradually gives the digestive system time to settle at each amount before the next increase. The OZEMPIC prescribing information is explicit that 0.25 mg is a starting dose and is not intended for glycemic control, which is why nobody is meant to stay there.
This matters because a lot of frustration comes from expecting results at week two. At 0.25 mg, the point is simply getting through the adjustment window. Judging the drug at the starting dose is like judging a car by how it idles in the driveway.
What are the actual dose steps?
The published Ozempic doses form a ladder with minimum times at each rung. The table below reflects the label schedule for type 2 diabetes.
| Dose | Minimum time at step | Role |
|---|---|---|
| 0.25 mg weekly | 4 weeks | Starting dose for tolerance only |
| 0.5 mg weekly | 4 weeks | First treatment dose |
| 1 mg weekly | 4 weeks before any further increase | Common maintenance dose |
| 2 mg weekly | Maintenance | Maximum approved dose |
The key detail people miss: these are minimums, not targets to rush. A prescriber can hold someone at 0.5 mg or 1 mg indefinitely if that dose is working and tolerated. Not everyone needs to reach 2 mg, and climbing higher for its own sake is not what the schedule asks for.
Why are the increases spaced four weeks apart?
Semaglutide has a long half-life, roughly a week, which is what allows once-weekly injection in the first place. Because it clears slowly, blood levels keep rising for several weeks after a dose change before they settle at a steady state. Waiting four weeks lets each new amount reach that plateau, so a prescriber can judge how the body responds to a stable level rather than a moving one. The pharmacology behind GLP-1 receptor agonists, reviewed in the literature on their mechanisms, explains why steady exposure rather than a spike drives the effect.
Pushing the schedule faster does not speed up benefit in any reliable way. It mostly front-loads side effects, which is the fastest route to stopping the medication altogether.
How is this different from the weight-loss version?
Ozempic and Wegovy share semaglutide as the active molecule, but they are approved for different uses and climb to different maximums. Ozempic is approved for type 2 diabetes and tops out at 2 mg weekly. Wegovy is approved for chronic weight management and titrates higher, to a 2.4 mg maintenance dose, following its own step schedule in the WEGOVY prescribing information. The trial evidence for weight outcomes, including STEP 3, STEP 4, and STEP 8, was built on that higher weight-management dosing rather than the diabetes schedule.
This distinction gets blurred constantly in casual conversation. When people say they are taking Ozempic for weight loss, they are describing off-label use of the diabetes product, which is a different situation from the approved Wegovy pathway. The FDA has published guidance on the semaglutide products marketed for diabetes and weight loss precisely because the naming causes so much confusion.
What about the shortage and compounded versions?
During recent supply pressure, compounded semaglutide became widely available through telehealth. It is worth being direct here: compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It has not been through the approval process behind the trial data that supports the brand versions, and its dosing does not necessarily match the brand titration steps. That is a real difference in the level of assurance, not a paperwork detail.
Cost is usually what drives people toward it. Where a plan will not cover the brand and self-pay is out of reach, flat monthly compounded pricing looks appealing, and supervised telehealth practices such as, as FormBlends explains, prescribe it under a licensed clinician rather than selling it as an off-the-shelf product. Anyone considering that route should still expect a titration plan set by a prescriber, because the reasons for a slow climb do not disappear just because the source changes. Instructions for measuring or injecting a compounded product without a prescriber involved are not something a reader should be assembling from an article.
What if a dose is missed?
The general label guidance is that a missed weekly dose can be taken within a few days if the next scheduled dose is still more than about two days away; otherwise the missed dose is skipped. The exact window is spelled out in the prescribing information, and it is one of the few places where following the label text precisely actually matters, since doubling up is not the fix.
Does the schedule ever end?
For most people, no. Semaglutide is used as an ongoing treatment, not a fixed course. The STEP 1 trial extension tracked what happened after withdrawal and found that participants regained a large share of lost weight over the following year, with related cardiometabolic measures drifting back too. That is not a failure of willpower; it is how the biology works once the drug is gone. The dose schedule is built to reach a sustainable maintenance amount and stay there, which is a different mindset from a program with a finish line.
Key takeaways
- Ozempic starts at 0.25 mg only to build tolerance; it is not a treatment dose.
- Steps rise every four weeks minimum, reflecting semaglutide’s slow, week-long clearance.
- Not everyone needs 2 mg; a lower tolerated dose that works is a valid endpoint.
- Ozempic and Wegovy differ in approved use and maximum dose despite the shared molecule.
- Compounded semaglutide is not FDA-approved and does not remove the need for a supervised titration plan.
See also: GHRP-2 Telehealth Providers in 2026: The Checklist I’d Run Before You Pay Anyone
Frequently asked questions
How long does it take to reach a full Ozempic dose?
The label schedule takes at least two months to reach 1 mg, starting at 0.25 mg for four weeks, then 0.5 mg for four weeks. Higher maintenance doses of 1 mg or 2 mg come only after more time at the prior step, so the earliest full titration spans several months.
Is the 0.25 mg starting dose supposed to control blood sugar?
No. The 0.25 mg dose is a starting dose meant only to reduce stomach side effects while the body adjusts. It is not intended as a treatment dose, which is why the schedule moves off it after four weeks.
Can the dose be increased faster if side effects are mild?
The label sets minimum times at each step, not maximums, so moving faster than the schedule is not what the prescribing information describes. If side effects are hard to tolerate, staying at a step longer is the usual adjustment a prescriber makes.
What happens to weight if the medication is stopped?
Trial data on semaglutide withdrawal showed that much of the lost weight returned over the following year. The dose schedule is built around continued use rather than a fixed course with an endpoint.
Is Ozempic the same schedule as Wegovy?
They share the active molecule but have different approved maximum doses and titration targets. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management and climbs to a higher maintenance dose.
